EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
Special Offer: Just $199
×
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:ATXI

Avenue Therapeutics - ATXI Stock Forecast, Price & News

$1.31
-0.06 (-4.38%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.30
▼
$1.44
50-Day Range
$1.31
▼
$67.50
52-Week Range
$1.30
▼
$26.85
Volume
214,226 shs
Average Volume
1.34 million shs
Market Capitalization
$6.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Avenue Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
1.44mentions of Avenue Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

See Top Rated MarketRank™ Stocks Here
ATXI stock logo

About Avenue Therapeutics (NASDAQ:ATXI) Stock

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXI Stock News Headlines

November 10, 2022 | finance.yahoo.com
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 8, 2022 | finance.yahoo.com
Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio
November 6, 2022 | msn.com
Reports of a vehicle fire on Anthony Wayne Avenue in Carthage
November 6, 2022 | msn.com
Reports of a vehicle fire on North Bend Road and Woodbine Avenue in Cheviot
November 6, 2022 | msn.com
2 juveniles injured following crash near 107th Avenue and Lower Buckeye Road, Phoenix police say
October 13, 2022 | msn.com
Looking Into Avenue Therapeutics's Recent Short Interest
October 12, 2022 | finance.yahoo.com
Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
October 11, 2022 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Avenue Therapeutics (ATXI), Eli Lilly & Co (LLY)
October 7, 2022 | marketwatch.com
Avenue Therapeutics Shares Slide Premarket After Offering Priced >ATXI
October 7, 2022 | benzinga.com
What In The World Is Going On With Avenue Therapeutics Stock?
October 5, 2022 | marketwatch.com
Avenue Therapeutics Shares Drop 34% After Public Offering Prices
October 3, 2022 | finance.yahoo.com
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
September 27, 2022 | marketwatch.com
Avenue Therapeutics Shareas Surge 160%
September 27, 2022 | nasdaq.com
Avenue Therapeutics Spikes 168%
September 26, 2022 | marketwatch.com
Avenue Therapeutics Shares Continue Reverse-Stock Split Slide
September 23, 2022 | marketwatch.com
Avenue Therapeutics Shares Down 38% After Reverse-Share Split
September 23, 2022 | markets.businessinsider.com
Avenue Therapeutics Sinks 25%; Shares Start Trading After Reverse Stock Split
September 23, 2022 | finance.yahoo.com
Avenue Therapeutics Announces Reverse Stock Split, Regulatory Update For Lead Its Pain Candidate
September 22, 2022 | marketwatch.com
Avenue Therapeutics Shares Rise After IV Tramadol Update, Reverse Split News
September 22, 2022 | seekingalpha.com
Avenue Therapeutics up 4% on 1-for-15 reverse stock split
September 22, 2022 | finance.yahoo.com
Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA
September 7, 2022 | msn.com
Take a look inside the new Avenue Pub space in downtown Tuscaloosa: ‘This is a long-term investment’
September 5, 2022 | nypost.com
Madison Avenue retail shows signs of life with six new stores
September 5, 2022 | msn.com
1 dead, multiple others hurt after multi-vehicle crash on I-75 south at Cleveland Avenue, APD says
June 29, 2022 | msn.com
BREAKING: Police at possible barricade situation near Druid Hill Avenue in Baltimore
See More Headlines
Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXI Company Calendar

Last Earnings
11/10/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/24/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATXI
CUSIP
N/A
CIK
1644963
Web
www.avenuetx.com
Phone
(781) 652-4500
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.7484)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,730,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-390.02%
Return on Assets
-268.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.94
Quick Ratio
0.94

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.72 per share
Price / Book
0.48

Miscellaneous

Outstanding Shares
4,779,000
Free Float
4,741,000
Market Cap
$6.26 million
Optionable
Not Optionable
Beta
-0.57

Key Executives

  • Dr. Lindsay Allan Rosenwald (Age 67)
    Exec. Chairman
  • Dr. Xiaoqin Lu M.D. (Age 47)
    Consultant
    Comp: $699.33k
  • Dr. Alexandra MacLean M.D. (Age 55)
    Chief Exec. Officer
  • Mr. David Jin
    Interim CFO & COO
  • Dr. Scott A. Reines M.D. (Age 75)
    Ph.D., Interim Chief Medical Officer
  • Srinivas Subramanian
    Exec. VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ATXI Stock - Frequently Asked Questions

How have ATXI shares performed in 2022?

Avenue Therapeutics' stock was trading at $13.62 at the beginning of 2022. Since then, ATXI stock has decreased by 90.4% and is now trading at $1.31.
View the best growth stocks for 2022 here.

Are investors shorting Avenue Therapeutics?

Avenue Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 82,900 shares, a decline of 61.0% from the October 31st total of 212,600 shares. Based on an average trading volume of 4,330,000 shares, the short-interest ratio is currently 0.0 days. Approximately 1.9% of the shares of the stock are short sold.
View Avenue Therapeutics' Short Interest.

When is Avenue Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023.
View our ATXI earnings forecast.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its quarterly earnings data on Thursday, November, 10th. The company reported ($0.45) EPS for the quarter.

When did Avenue Therapeutics' stock split?

Avenue Therapeutics's stock reverse split on Friday, September 23rd 2022. The 1-15 reverse split was announced on Friday, September 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Avenue Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO).

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

Who are Avenue Therapeutics' major shareholders?

Avenue Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (2.42%) and Two Sigma Investments LP (0.97%). Insiders that own company stock include Invagen Pharmaceuticals, Inc, Joseph Walter Vazzano and Neil Herskowitz.
View institutional ownership trends.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $1.31.

How much money does Avenue Therapeutics make?

Avenue Therapeutics (NASDAQ:ATXI) has a market capitalization of $6.26 million. The company earns $-3,730,000.00 in net income (profit) each year or ($3.7484) on an earnings per share basis.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The official website for the company is www.avenuetx.com. The company can be reached via phone at (781) 652-4500 or via email at ir@avenuetx.com.

This page (NASDAQ:ATXI) was last updated on 11/29/2022 by MarketBeat.com Staff